A phase i clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer

Chemotherapy

Volumn 58, Issue 4, 2012, Pages 257-263

  Crabb, Simon J ^a,b   Bradbury, Jennifer ^a   Nolan, Luke ^a   Selman, Diana ^b   Muthuramalingam, Sethupathi R ^c   Cave, Judith ^a   Johnson, Peter W M ^a,b   Ottensmeier, Christian ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Chemotherapy; Irinotecan; Phase I; Small cell lung cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ATROPINE; CARBOPLATIN; CIPROFLOXACIN; CODEINE PHOSPHATE; CREATININE; ETOPOSIDE; IRINOTECAN; LOPERAMIDE; PLATINUM;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTIBIOTIC THERAPY; ANXIETY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HALLUCINATION; HUMAN; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; INSOMNIA; LEG PAIN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINORRHEA; SEPSIS; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; WEIGHT REDUCTION;

ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; CARBOPLATIN; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SEPSIS; SMALL CELL LUNG CARCINOMA; THROMBOSIS;

EID: 84865058541     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000341274     Document Type: Article

References (16)

1. Rodriguez E, Lilenbaum RC: Small cell lung cancer: past, present, and future. Curr Oncol Rep 2010; 12: 327-334.
2. Chute JP, Chen T, Feigal E, Simon R, Johnson BE: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 1794-1801.
3. Sambrook RJ, Girling DJ: A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Br J Cancer 2001; 84: 1447-1452.
4. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T, Saijo N: Randomised phase III trial of carboplatin plus etoposide vs. split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007; 97: 162-169.
5. Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study-Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994; 21: 23-30.
6. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
7. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-5159.
8. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
9. Lara PN, Jr., Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27: 2530-2535.
10. Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038-2043.
11. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M: A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010; 21: 1810-1816.
12. Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrom S, Thaning L, Vilsvik J, Aasebo U, Sorenson S: Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26: 4261-4267.
13. Gandara DR, Lara PN, Jr., Natale R, Belani C: Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol 2008; 26: 4236-4238.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors-European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Al-Dasooqi N, Bowen JM, Gibson RJ, Logan RM, Stringer AM, Keefe DM: Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy 2011; 57: 43-53.
16. Wallin AP, Francis P, Nilbert M, Svanvik J, Sun XF: Gene expression profile of colon cancer cell lines treated with SN-38. Chemotherapy 2010; 56: 17-25.